PRETT
Revolutionising cancer treatment, PreTT pioneers best-in-class Pretargeted radioligand therapies, surpassing traditional methods. Our exclusive pretargeting technology is set to transform radioimmunotherapies with monoclonal antibodies (mAbs), making a tangible impact in the fight against cancer.
BACKGROUND
Radioligand Therapy (RLT) is a highly effective and more delicate way to treat tumours by using radiation. Radioligand Therapy works not only where chemotherapies fail, but also in the treatment of naïve patients.
TECHNOLOGY
RLT has mainly been based on peptides. mAbs would often be preferred as they can be easier developed with respect to production, selectivity and radionuclide conjugation. Unfortunately, and in contrast to many peptides, mAbs accumulate slowly into cancers and excrete slowly from the rest of the body. This characteristic disqualifies mAbs for almost all RLTs as the initial radiation represents a burden on healthy tissues and limits the dose that can be administered. Our pretargeting platform, which separates the (non-radioactive) mAb accumulation and excretion from the actual radiotherapy, circumvents this intrinsic radiotoxicity challenge.
